SCHEDULE: Armistice Capital Reports 9.99% Stake in Calidi Biotherapeutics

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Calidi Biotherapeutics, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC, an investment manager, and Steven Boyd, its managing member, have filed a Schedule 13G indicating beneficial ownership of 1,111,732 shares of Calidi Biotherapeutics, Inc. common stock.
• This holding represents 9.99% of the class of securities.
• The shares are directly held by Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital.
• Armistice Capital exercises voting and investment power over the securities held by the Master Fund.
• Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own these securities.
• The Master Fund disclaims beneficial ownership due to the Investment Management Agreement with Armistice Capital.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data, making it purely informational regarding ownership structure.

Positives

• Significant stake reported by a known investment entity, potentially indicating confidence in the company's future.
• The filing is current as of March 31, 2026, providing up-to-date ownership information.

Negatives

• The filing does not provide details on the acquisition cost or strategy behind the stake.
• No specific performance metrics or financial results are discussed in this ownership filing.

Risks

• Potential for increased market volatility if Armistice Capital decides to significantly alter its position.
• Concentration of ownership by a single entity could influence corporate governance decisions.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. This filing indicates a significant passive investment in the biotechnology sector, a field often characterized by high growth potential and substantial risk.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant ownership block, which could influence market perception and trading activity.
• Management: The presence of a substantial shareholder may lead to increased scrutiny or engagement regarding company strategy and performance.

Next Steps

• Monitor future filings from Armistice Capital for any changes in ownership or potential activist involvement.
• Review Calidi Biotherapeutics' operational and financial reports for performance updates.

Key Dates

Keywords

Schedule 13G, Calidi Biotherapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management